Xenon Pharmaceuticals
Stock Forecast, Prediction & Price Target
Xenon Pharmaceuticals Financial Estimates
Xenon Pharmaceuticals Revenue Estimates
Xenon Pharmaceuticals EBITDA Estimates
Xenon Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $18.43M N/A | $9.43M -48.83% | $0 -100% | Avg: $9.38M Low: $9.38M High: $9.38M avg. 0% | Avg: $60.58M Low: $60.58M High: $60.58M avg. 545.30% | Avg: $366.81M Low: $366.81M High: $366.81M avg. 505.45% | Avg: $646.66M Low: $646.66M High: $646.66M avg. 76.29% |
Net Income
% change YoY
| $-78.88M N/A | $-125.37M -58.93% | $-182.39M -45.48% | Avg: $-268.68M Low: $-282.94M High: $-68.22M avg. -47.31% | Avg: $-305.88M Low: $-311.70M High: $-107.69M avg. -13.84% | Avg: $-59.36M Low: $-59.36M High: $-59.36M avg. 80.59% | Avg: $96.06M Low: $96.06M High: $96.06M avg. 261.83% |
EBITDA
% change YoY
| $-78.99M N/A | $-129.14M -63.48% | $-210.51M -63.00% | Avg: $-5.58M Low: $-5.58M High: $-5.58M avg. 97.34% | Avg: $-36.02M Low: $-36.02M High: $-36.02M avg. -545.30% | Avg: $-218.11M Low: $-218.11M High: $-218.11M avg. -505.45% | Avg: $-384.52M Low: $-384.52M High: $-384.52M avg. -76.29% |
EPS
% change YoY
| -$1.81 N/A | -$2.07 -14.36% | -$2.73 -31.88% | Avg: -$3.2 Low: -$4.23 High: -$1.02 avg. -17.10% | Avg: -$3.39 Low: -$4.66 High: -$1.61 avg. -6.06% | Avg: -$0.89 Low: -$0.89 High: -$0.89 avg. 73.82% | Avg: $1.44 Low: $1.44 High: $1.44 avg. 261.83% |
Operating Expenses
% change YoY
| $97.43M N/A | $138.57M 42.23% | $46.54M -66.41% | Avg: $14.37M Low: $14.37M High: $14.37M avg. -69.12% | Avg: $92.73M Low: $92.73M High: $92.73M avg. 545.30% | Avg: $561.49M Low: $561.49M High: $561.49M avg. 505.45% | Avg: $989.87M Low: $989.87M High: $989.87M avg. 76.29% |
FAQ
What is Xenon Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 70.31% in 2025-2028.
We have gathered data from 13 analysts. Their low estimate is -282.94M, average is -268.68M and high is -68.22M.
What is Xenon Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 281.76% in 2025-2028.
We have gathered data from 10 analysts. Their low revenue estimate is $9.38M, average is $9.38M and high is $9.38M.
What is Xenon Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 78.12% in 2025-2028.
We have gathered data from 13 analysts. Their low earnings per share estimate is -$4.23, average is -$3.2 and high is $-1.02.
What is the best performing analyst?
In the last twelve months analysts have been covering Xenon Pharmaceuticals stock. The most successful analyst is Danielle Brill.